Zuwei Jin, VP of Business Development at LISURE explains the advantages of the M++ system at BioProcess International US West 2025 in San Diego, CA. M++ is a pilot-scale modular benchtop system that ...

Ingress of carbon dioxide into bulk drug substance (BDS) containers that are stored and shipped on dry ice is a serious and often understated problem. Bottles are a container of choice for freezing ...

In this informative white paper, WuXi Biologics delves into how WuXi Biologics addressed the critical need for speed in moving biologics from DNA to Investigational New Drug (IND) application ...

Join our 70,000+ readers. And yes, it's completely free.

Biopharmaceutical manufacturers often implement corrective and preventive actions (CAPAs) as a mitigation strategy to address deviations based on root causes identified in investigations of process ...

This interview features: Lee Willmon, HSE Operations, Novartis, from BPI West 2024.

As of its 2023 guidance on combination and boundary products, the Australian Therapeutic Goods Administration (TGA) has provided context around key regulated product categories: Combination products ...

Demand has surged for good manufacturing practice (GMP)–grade plasmid DNA (pDNA) used in late-phase clinical trials and commercial manufacturing due to the starting material’s critical role in ...

We at BPI had so much fun putting together our big anniversary retrospective issue last year that we decided to make it an annual tradition starting this year — albeit on a bit smaller scale. There’s ...

Explore the latest news and expert commentary on Cell Culture Media, brought to you by the editors of BioProcess International ...

Explore the latest news and expert commentary on Continuous Bioprocessing, brought to you by the editors of BioProcess International ...

This special summer issue serves as an “expression platform” for as many different industry voices as we could squeeze in between our front and back covers. To get even more points of view than our ...